



Kern Pharma – Portfolio 2010

Dossier	Availability
ALENDRONATE 70 mg tablets	Available
BETAHISTINE 8 mg, 16 mg tablets	Available
BROMAZEPAM 1,5 mg and 3 mg capsules	Available
CANDESARTAN 4 mg, 8 mg, 16 mg, 32mg tablets	Available
CLOPERASTINE 17.7mg/5 ml, oral solution	Available
CLORAZEPIC ACID 5 mg, 10 mg, 15 mg capsules	Available
DICLOFENAC DIETHYLAMMONIUM 1% gel	Available
DIOSMIN/HESPERIDIN 450/50 mg tablets	Available
FENTANYL (CITRATE) SOLUTION FOR INJECTION 0.05 mg/ml; 2ml, 5ml, 10ml ampoules	Available
FINASTERIDE 1 mg, tablets	Available
FUROSEMIDE 40 mg tablets	Available
HALOPERIDOL 2 mg/ml oral solution	Available
HYDROCHLOROTHIAZIDE 50 mg tablets	Available
IBUPROFEN 200 mg and 600 mg effervescent granules sachets	Available
IRBESARTAN 75 mg, 150 mg and 300 mg	Available



Sorprendemos

Dossier	Availability
IRBESARTAN/HCT 150/12,5 mg; 300/12,5 mg;300/25 mg tablets	Available
LATANOPROST 0,005% eye drops	Available
LETROZOLE 2,5 mg tablets	Available
LORMETAZEPAM 1 mg and 2 mg tablets	Available
LOSARTAN 50 mg and 100 mg tablets	Available
METOCLOPRAMIDE 1mg/ml, oral solution	Available
NEVIRAPINE 200 mg, tablets	Available
OLANZAPINE 2,5 mg, 5 mg, 7,5 and 10 mg tablets	Available
PARACETAMOL 500 mg tablets	Available
PARACETAMOL 1000 mg tablets	Available
PARACETAMOL 100mg/ml oral solution	Available
PARACETAMOL/CODEINE 500/30 mg tablets	Available
PARACETAMOL – TRAMADOL 325/37,5mg tablets	Available
PREDNISON 5 mg and 30 mg tablets	Available
REMIFENTANIL 1 mg, 2mg and 5 mg vials	Available
SULPIRIDE 50 mg capsules	Available
TERBINAFINE 250 mg tablets	Available
TROXERUTIN 500mg/5ml oral solution	Available



Currently on-going developments

DONEPEZIL ODT 5mg, 10 mg,	Q4 2010
MEMANTINE 10mg, 20 mg, tablets	Q4 2010
MEMANTINE 10mg/g, Oral drops	Q4 2010
TELMISARTAN 20, 40, 80 mg tablets	Q4 2010
EFAVIRENZ 600mg, film coated tablets	Q2 2011
CELECOXIB 200 mg, capsules	Q2 2011
DEXKETOPROFEN TROMETAMOL 12.5mg, 25mg tablets	Q2 2011
DESLORATADINE 5 mg tablets	Q4 2011
PREGABALIN 25 mg, 50 mg, 75 mg, 100mg, 150mg, 200mg, 225mg, 300mg	Q4 2011